银杏叶提取物作为佐剂治疗二甲双胍无效的2型糖尿病患者的疗效和安全性:一项双盲、随机、安慰剂对照试验。

PubMed ID
发表日期 2018年月

原始出处 药物设计、开发和治疗
Drug design, development and therapy
作者 Aziz  Tavga Ahmed  Hussain  Saad Abdulrahman  Mahwi  Taha Othman  Ahmed  Zheen Aorahman  Rahman  Heshu Sulaiman  Rasedee  Abdullah 

文献标题 银杏叶提取物作为佐剂治疗二甲双胍无效的2型糖尿病患者的疗效和安全性:一项双盲、随机、安慰剂对照试验。
The efficacy and safety of Ginkgo biloba extract as an adjuvant in type 2 diabetes mellitus patients ineffectively managed with metformin: a double-blind, randomized, placebo-controlled trial.

文献摘要 Background and aim

2型糖尿病(T2DM)是卫生保健系统面临的主要疾病之一。在糖尿病(DM)患者中,口服降糖药的联合应用比单用二甲双胍(Met)更有效。本研究探讨银杏叶提取物(GKB)对非控制性T2DM患者Met的辅助治疗作用。

Subjects and methods

采用随机、安慰剂对照、双盲、多中心试验,招募60名2型糖尿病患者。目前使用Met的患者被随机分为GKB提取物(120mg/天)或安慰剂(淀粉,120mg/天)治疗90天。测定GKB提取物治疗前(基线)和治疗后90天血糖、空腹血糖、血清胰岛素、体重指数(BMI)、腰围(WC)、胰岛素抵抗和内脏脂肪指数(VAI)。

Results

厘米与基线106.0±10.9cm,P<0.001)和VAI(158.9±67.2 vs基线192.0±86.2,P=0.007)。GKB提取物对肝、肾或造血功能没有负面影响。

Conclusion

GKB提取物作为佐剂对改善T2DM患者的Met治疗效果有效。因此,GKB提取物是控制人类糖尿病的有效膳食补充剂。


Background and aim

Type 2 diabetes mellitus (T2DM) is one of the major diseases confronting the health care systems. In diabetes mellitus (DM), combined use of oral hypoglycemic medications has been shown to be more effective than metformin (Met) alone in glycemic control. This study determined the effects of Ginkgo biloba (GKB) extract as an adjuvant to Met in patients with uncontrolled T2DM.

Subjects and methods

Sixty T2DM patients were recruited in a randomized, placebo-controlled, double-blinded, and multicenter trial. The patients, currently using Met, were randomly grouped into those treated with either GKB extract (120 mg/day) or placebo (starch, 120 mg/day) for 90 days. Blood glycated hemoglobin (HbA1c), fasting serum glucose, serum insulin, body mass index (BMI), waist circumference (WC), insulin resistance, and visceral adiposity index (VAI) were determined before (baseline) and after 90 days of GKB extract treatment.

Results

GKB extract significantly decreased blood HbA1c (7.7%±1.2% vs baseline 8.6%±1.6%, P<0.001), fasting serum glucose (154.7±36.1 mg/dL vs baseline 194.4±66.1 mg/dL, P<0.001) and insulin (13.4±7.8 μU/mL vs baseline 18.5±8.9 μU/mL, P=0.006) levels, BMI (31.6±5.1 kg/m2 vs baseline 34.0±6.0 kg/m2, P<0.001), waist WC (102.6±10.5 cm vs baseline 106.0±10.9 cm, P<0.001), and VAI (158.9±67.2 vs baseline 192.0±86.2, P=0.007). GKB extract did not negatively impact the liver, kidney, or hematopoietic functions.

Conclusion

GKB extract as an adjuvant was effective in improving Met treatment outcomes in T2DM patients. Thus, it is suggested that GKB extract is an effective dietary supplement for the control of DM in humans.


获取全文 10.2147/DDDT.S157113